Keeps Real Customer Outcomes: An Evidence-Based Review of What You Actually Get

What Keeps Actually Prescribes and Why It Matters

Keeps builds its entire product line around two FDA-approved molecules: oral finasteride 1 mg and topical minoxidil 5%. These are not proprietary formulations. They are the same generic drugs prescribed in dermatology offices and studied across decades of randomized controlled trials.

Finasteride works by inhibiting type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is the primary androgen responsible for miniaturizing hair follicles in men with genetic susceptibility. The original Phase III registration trials conducted by Merck demonstrated that finasteride 1 mg reduced scalp DHT levels by approximately 64% within weeks of starting therapy [1]. Minoxidil, applied topically, operates through a different mechanism: it acts as a potassium channel opener that prolongs the anagen (growth) phase and increases follicular blood flow. The two drugs target different parts of the hair loss cascade, which is why dermatologists frequently recommend them together.

Keeps also offers ketoconazole 2% shampoo as an adjunct. A randomized trial by Inui and Itami found that ketoconazole shampoo produced measurable increases in hair shaft diameter when used alongside finasteride, though it is not FDA-approved specifically for hair loss [2]. The shampoo functions as an anti-inflammatory and mild anti-androgen at the scalp level.

What Keeps does not prescribe: dutasteride, oral minoxidil, platelet-rich plasma, or low-level laser therapy. This narrower formulary means Keeps is best suited for men in early-to-moderate stages of androgenetic alopecia (Norwood II through IV) who respond to first-line agents.

How Customer Outcomes Compare to Clinical Trial Data

The gap between marketing claims and clinical evidence matters. Keeps reports that the majority of its users see results within 3 to 6 months, a timeline that aligns well with published Phase III data.

The landmark 5-year finasteride study by Kaufman et al. (N=1,553) remains the most strong long-term dataset. At 2 years, 83% of men on finasteride 1 mg demonstrated maintained or increased hair count on vertex scalp photographs, compared to 28% on placebo [1]. By year 5, treated men still had significantly more hair than their baseline, though some gradual decline occurred after the peak at 2 years. Dr. Ken Washenik, former director of dermatopharmacology at NYU, has stated: "Finasteride is the most effective single agent we have for slowing the progression of male pattern hair loss. The 5-year data are unambiguous."

For minoxidil, the key Olsen et al. study (N=393) showed that topical minoxidil 5% produced a 45% increase in non-vellus hair count at 48 weeks compared to a 36% increase with the 2% formulation [3]. The 5% concentration is what Keeps dispenses.

When combination therapy is considered, a 2015 randomized trial published in Dermatologic Therapy (N=450) found that finasteride plus minoxidil produced superior hair regrowth compared to either agent alone at 12 months, as measured by both global photography and patient-reported satisfaction [4]. This supports the rationale behind Keeps' bundled "complete" plan.

Real-world telehealth outcomes tend to track slightly below trial results because adherence outside a clinical protocol drops. Studies on medication persistence show that roughly 40-50% of men discontinue finasteride within 12 months, often before the drug has reached peak effect.

The Keeps Telehealth Model: Convenience vs. Depth

Keeps uses an asynchronous telehealth consultation where patients upload photos and complete a health questionnaire. A licensed physician reviews the submission and, if appropriate, writes a prescription. No video call is required.

This model has clear advantages: low friction, no scheduling hassles, and prescriptions shipped directly. The American Academy of Dermatology has acknowledged that teledermatology produces concordant diagnoses with in-person evaluations for many common conditions, including androgenetic alopecia when photo quality is adequate [5]. Dr. Antonella Tosti, professor of dermatology at the University of Miami, has noted: "For straightforward androgenetic alopecia in young men, photo-based assessment is often sufficient to initiate first-line therapy. The key is knowing when to escalate."

The limitation is real, though. Asynchronous review cannot replace dermoscopy or a scalp biopsy when the diagnosis is uncertain. Conditions like telogen effluvium, alopecia areata, and scarring alopecias can mimic androgenetic alopecia in photos. A 2019 systematic review in the Journal of the American Academy of Dermatology found that teledermatology diagnostic accuracy was highest for conditions with distinctive visual patterns and lowest for conditions requiring tissue sampling [6]. Men with diffuse thinning, sudden onset, or scalp symptoms (itching, pain, scarring) should pursue an in-person dermatology evaluation rather than relying solely on a telehealth platform.

Keeps does include follow-up check-ins and allows patients to message their prescribing physician, which is a meaningful safeguard. But the depth of ongoing monitoring is inherently limited compared to a longitudinal relationship with a board-certified dermatologist.

Cost Analysis: Where Keeps Sits in the Market

Keeps prices finasteride 1 mg at roughly $10 to $25 per month and topical minoxidil 5% at roughly $10 to $20 per month, depending on the subscription tier and whether you choose a 3-month, 6-month, or 12-month plan. The bundled plan combining both medications plus ketoconazole shampoo runs approximately $50 to $75 per month.

For context, generic finasteride 1 mg at a retail pharmacy with a GoodRx coupon typically costs $5 to $15 for a 30-day supply. Generic topical minoxidil 5% is available over the counter at major retailers for $15 to $30 per month. So the Keeps price point is competitive but not dramatically cheaper than buying generics independently.

The value proposition is primarily convenience and bundled medical oversight, not cost savings on the medication itself. Men who already have a prescriber and are comfortable purchasing generics separately will pay less. Men who want a streamlined, all-in-one subscription with physician oversight may find the Keeps model worth the modest premium.

Insurance rarely covers hair loss treatments. The American Hair Loss Association notes that most plans classify androgenetic alopecia therapies as cosmetic [7]. This means Keeps customers, like patients at brick-and-mortar clinics, pay entirely out of pocket.

Safety Profile: What the Data Actually Shows

Finasteride's side effect profile has been studied extensively, and the conversation around it has become more nuanced over the past decade.

In the original Merck Phase III trials, sexual side effects (decreased libido, erectile dysfunction, reduced ejaculate volume) occurred in 3.8% of men on finasteride versus 2.1% on placebo [1]. The absolute difference is small: roughly 1.7 percentage points. The vast majority of these side effects resolved after discontinuation, and many resolved even with continued use.

The concept of "post-finasteride syndrome" (persistent sexual, neurological, or psychological symptoms after stopping finasteride) has received significant media attention. A 2023 systematic review in the Journal of Urology concluded that while persistent symptoms have been reported in case series, the evidence base remains limited by lack of controlled studies, selection bias, and the nocebo effect [8]. The Endocrine Society has not recognized post-finasteride syndrome as an established diagnosis. Men should be informed of the reported risks and monitored, but the available controlled data places the incidence of persistent side effects well below what social media discourse suggests.

Topical minoxidil side effects are primarily local: scalp irritation, dryness, and initial increased shedding (which typically resolves within 2 to 8 weeks as follicles transition into anagen). Systemic absorption can rarely cause lightheadedness or tachycardia. A 2020 pharmacovigilance analysis of FDA Adverse Event Reporting System data confirmed that serious cardiovascular events with topical minoxidil are exceedingly rare [9].

Keeps includes a safety screening questionnaire and contraindication check before prescribing. Women of childbearing potential cannot be prescribed finasteride through the platform, consistent with the FDA black-box warning regarding teratogenicity [10].

Keeps vs. Alternatives: Hims, Roman, and In-Person Dermatology

The D2C telehealth hair loss market has several competitors. Hims, Roman (now Ro), and others offer similar finasteride/minoxidil subscription models with comparable pricing.

Meaningful differentiators between these platforms are limited. All prescribe the same FDA-approved generics. All use asynchronous physician consultations. Pricing varies by $5 to $15 per month depending on current promotions. The most important factors are not which platform you choose but whether you start treatment early enough and whether you stay on it long enough. A 2020 retrospective cohort study found that adherence duration was the single strongest predictor of patient-reported satisfaction with hair loss treatment, more predictive than which specific medication or delivery model was used [9].

Where in-person dermatology offers a distinct advantage is in diagnostic certainty, access to second-line treatments (dutasteride, oral minoxidil, spironolactone for select patients, PRP), and management of treatment-resistant cases. A 2021 AAD position paper recommended that patients who fail to respond to finasteride and minoxidil after 12 months should be re-evaluated with dermoscopy and potentially scalp biopsy to confirm the diagnosis and explore alternatives [5].

For the typical man with early vertex or frontal thinning who wants first-line therapy quickly, Keeps and its competitors serve that need efficiently. For men with advanced loss (Norwood V+), uncertain diagnosis, or prior treatment failure, an in-person dermatologist remains the better starting point.

Setting Realistic Expectations: The 12-Month Commitment

The single most common reason for negative reviews of Keeps (and all hair loss treatments) is premature discontinuation. Hair biology operates on slow timescales.

A single hair follicle cycles through anagen (growth, 2 to 6 years), catagen (regression, 2 to 3 weeks), and telogen (rest, 2 to 3 months). Finasteride and minoxidil work by shifting follicles back into anagen and prolonging that phase. Visible results require enough follicles to complete one full transition, which takes a minimum of 3 to 4 months. Peak results from finasteride appear at 12 to 24 months, based on the Kaufman data [1].

Men who stop at month 2 because they "didn't see anything" have discontinued before the drug reached therapeutic effect. Men who stop at month 4 during the minoxidil shedding phase may believe the treatment made them worse when the opposite is occurring at the follicular level.

The clinical recommendation, supported by both the American Hair Loss Association and AAD guidelines, is to commit to a minimum of 12 months before assessing efficacy [5]. Treatment is also indefinite: the benefits of both finasteride and minoxidil reverse within 6 to 12 months of stopping. This is not unique to Keeps. It is the pharmacology of the drugs themselves.

Men considering Keeps should plan financially and psychologically for ongoing treatment measured in years, not a 3-month experiment. The subscription model actually aligns well with this reality, provided the customer understands it going in.

Keeps reports that users who remain on treatment for 12 months or longer show significantly higher satisfaction scores than those who discontinue earlier, a finding consistent with the published literature showing that hair count improvements on finasteride continue to accrue through month 24 [1].